Could a diabetes pill boost heart health in fontan patients?

NCT ID NCT07482943

Not yet recruiting Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug already approved for diabetes and heart failure, can improve exercise ability and heart function in people who have had the Fontan procedure. About 30 participants aged 12 and older will take the drug daily for 3 months. The goal is to see if it helps them use oxygen more efficiently during exercise, which could mean better daily life and fewer hospital visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder congenital heart disease heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES DAPAGLIFLOZIN FONTAN HEART FAILURE SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital

Hong Kong, Hong Kong

Contact Phone: •••-•••-•••• Email: •••••@•••••
Queen Mary Hospital

Hong Kong, Hong Kong

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.